Open AccessProthrombotic and Inflammatory Effects of Intravenous Administration of Human Immunoglobulin G in Dogs
Author(s) -
Tsuchiya R.,
Akutsu Y.,
Ikegami A.,
Scott M.A.,
Neo S.,
Ishikawa T.,
Hisasue M.,
Yamada T.
Publication year - 2009
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2009.0402.x
Subject(s) - medicine , beagle , fibrinogen , leukopenia , saline , fibrin , inflammation , coagulopathy , antithrombin , platelet , gastroenterology , anesthesia , immunology , toxicity , heparin
Background: Intravenous administration of human immunoglobulin G (hIVIgG) has been suggested to potentiate thromboembolism in dogs, but supportive scientific reports are lacking. Objectives: To determine if hIVIgG therapy promotes hypercoagulability and inflammation in dogs. Animals: Twelve healthy Beagle dogs. Methods: Prospective, experimental trial. An hIVIgG/saline solution was infused IV at 1 g/kg BW over 8 hours to 6 dogs, and physiological saline was infused to the other 6 dogs. Blood samples were drawn before, during, and after infusion for serial measurement of indicators of coagulation and inflammation. Data were analyzed by 2‐way repeated measures analysis of variance. Results: Dogs administered hIVIgG developed mildly decreased blood platelet concentrations without thrombocytopenia (median, 200 × 10 3 /μL; range, 150–302 × 10 3 /μL; P < .01), leukopenia (median, 3.5 × 10 3 /μL; range, 20–62 × 10 3 /μL; P < .001), and mildly increased plasma total protein concentrations (median, 6.3 g/dL; range, 5.6–6.7 g/dL; P < .001). Administration of hIVIgG was also associated with increases in fibrin/fibrinogen degradation products in all dogs (either 5 μg/mL or 10 μg/dL), thrombin‐antithrombin III complexes (median, 7.2 ng/mL; range, 4.9–14.2 ng/mL; P < .001), and C‐reactive protein concentrations (median, 2.5 mg/dL; range, 0.5–4.3 mg/dL; P < .01). Conclusion and Clinical Importance: Administration of hIVIgG to dogs promotes hypercoagulability and an inflammatory state. This should be further evaluated and considered when using hIVIgG in dogs with IMHA or other prothrombotic conditions.